Regulus Therapeutics Inc. (RGLS): Price and Financial Metrics


Regulus Therapeutics Inc. (RGLS): $1.44

0.03 (+2.13%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add RGLS to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

RGLS Stock Price Chart Interactive Chart >

Price chart for RGLS

RGLS Price/Volume Stats

Current price $1.44 52-week high $3.70
Prev. close $1.41 52-week low $1.08
Day low $1.40 Volume 50,804
Day high $1.50 Avg. volume 44,715
50-day MA $1.48 Dividend yield N/A
200-day MA $1.84 Market Cap 21.07M

Regulus Therapeutics Inc. (RGLS) Company Bio


Regulus Therapeutics is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. The company was founded in 2007 and is based in San Diego, California.


RGLS Latest News Stream


Event/Time News Detail
Loading, please wait...

RGLS Latest Social Stream


Loading social stream, please wait...

View Full RGLS Social Stream

Latest RGLS News From Around the Web

Below are the latest news stories about REGULUS THERAPEUTICS INC that investors may wish to consider to help them evaluate RGLS as an investment opportunity.

Regulus Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the grant of an inducement stock option to Claire Padgett, Ph.D. and to Rekha Garg, M.D., M.S., on January 11, 2023 in connection with their respective appointments as Regulus' Senior Vice President, Clinical Operations and Senior Vice President, Clinical Development and Regulatory. The grants in a

Yahoo | January 13, 2023

Sanofi Opts To Terminate Rare Disease Program With Regulus Therapeutics

Sanofi SA (NASDAQ: SNY) elected to terminate its second amended and restated collaboration and license agreement with Regulus Therapeutics Inc (NASDAQ: RGLS), initially announced in 2014. In July 2022, Sanofi decided to terminate the Phase 2 clinical study of lademirsen for Alport syndrome for failure to meet Sanofi’s pre-defined futility criteria. Safety issues forced a revamp of that late-stage program when Sanofi flagged a failure for its microRNA drug lademirsen. At that time, Sanofi was eva

Yahoo | January 9, 2023

Regulus Therapeutics Announces Resignation of Board Member

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that Simos Simeonidis, Ph.D., member of the Board of Directors, has stepped down from the Board, due to the time requirements of his recent appointment as co-Chief Executive Officer and co-Chief Investment Officer at Ally Bridge Group. His resignation was effective December 6, 2022.

Yahoo | December 12, 2022

13 Best Biotech Penny Stocks To Buy Now

In this article, we will be taking a look at the 13 best biotech penny stocks to buy now. To skip our detailed analysis of these stocks, you can go directly to see the 5 Best Biotech Penny Stocks To Buy Now. Biotechnology is a sector that has long been contributing to the improvement of […]

Yahoo | November 29, 2022

Regulus Therapeutics Announces Appointments of Industry Veterans, Drs. Rekha Garg and Claire Padgett, to Lead Clinical Development, Regulatory and Clinical Operations

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the appointments of Rekha Garg, M.D., M.S., to Senior Vice President, Clinical Development and Regulatory, and Claire Padgett, Ph.D. to Senior Vice President, Clinical Operations. The company also announced the promotion of Morgan Carlson, Ph.D., to Vice President, Biology and Edmund Lee, Ph.D., to

Yahoo | November 29, 2022

Read More 'RGLS' Stories Here

RGLS Price Returns

1-mo 5.11%
3-mo -0.69%
6-mo -15.29%
1-year -41.63%
3-year -86.67%
5-year -99.00%
YTD 5.11%
2022 -56.51%
2021 -76.67%
2020 51.69%
2019 -4.30%
2018 -92.55%

Continue Researching RGLS

Here are a few links from around the web to help you further your research on Regulus Therapeutics Inc's stock as an investment opportunity:

Regulus Therapeutics Inc (RGLS) Stock Price | Nasdaq
Regulus Therapeutics Inc (RGLS) Stock Quote, History and News - Yahoo Finance
Regulus Therapeutics Inc (RGLS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8005 seconds.